Sign in
Taking people in NetherlandsPhase 2

Tests esketamine nasal spray in adults with hard-to-treat bipolar depression

Tests esketamine nasal spray in adults with bipolar depression that has not responded to treatment.

Key facts

Who runs it
Academisch Ziekenhuis Leiden
Where
Leiden, NetherlandsSee the site
Registry title
Esketamine nasal spray (Spravato) for the treatment of therapy-resistant bipolar depression. An open-label pilot trial.
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
1 Apr 2025
Planned end
1 Apr 2025
Type of study
Interventional
Record updated
26 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with bipolar I or II disorder who are in a depressive episode and have not responded to at least two earlier medicines.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Bipolar I or II disorder, currently in a depressive episode with a MADRS score above 18, and treatment-resistant: no response to at least two different antidepressants or mood stabilizers.
Earlier treatment
No response to at least two different antidepressant or mood-stabilizing medicines at a sufficient dose for a sufficient time. Currently on a mood stabilizer, with no more than five antidepressant therapies for this episode. Medication at a stable dose for at least two weeks.

Main reasons for not taking part

  • Allergy to esketamine or its excipients
  • Recreational ketamine use now or in the past 6 months, or ketamine use disorder in their lifetime
  • Previous treatment with esketamine or earlier part in an esketamine trial
  • Pregnancy (blood test at baseline) or breastfeeding
  • Psychotic depression, or suicidal to the point that closed admission is needed or C-SSRS is four or higher

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Diagnosis of bipolar I or II disorder
  • Age between 18 and 75
  • MADRS scores above 18
  • Current episode of depression
  • Meeting the criteria of a current treatment resistant depression defined as a failure to respond to at least two different antidepressant or mood stabilizing agents during a sufficient amount of time at a sufficient dosage
  • Currently be on treatment with a mood stabilizer, but may not have been treated with more than five anti-depressant therapies for the current episode
  • Medication at a stable dosage for at least two weeks
  • Availability on Monday and Friday

Who cannot take part

  • Previously been treated with esketamine or have been part of an esketamine trial
  • Known allergies against esketamine, or it's excipients
  • Known cardiovascular problems that could result in severe side effects due to a rise of blood pressure, for example: intracranial, abdominal or thoracic aneurysms and patients with recent cardiovascular events (less than six weeks ago), such as a myocardial infarction
  • Ketamine use disorder in their lifetime as assessed with the MINI
  • An active alcohol- or drug use disorder as assessed with the MINI
  • Using ketamine in a recreative manner at present, or with recreative use in the past 6 months
  • Women who are breastfeeding
  • Unable to follow instructions or unable to make their own decisions regarding treatment
  • Pregnancy as measured with a blood test at baseline
  • Suicidal to a point where closed admission is needed or the C-SSRS is four or higher
  • Psychosis (psychotic depression) as assessed with the MINI

Where in Netherlands

  • Academisch Ziekenhuis LeidenLeiden, NetherlandsTaking people

About the trial

What the trial wants to find out

The study is an open-label pilot study of esketamine nasal spray in patients with treatment-resistant bipolar depression to assess efficacy in global, but most importantly safety and tolerability. At the current stage of drug trials involving re-designation of esketamine nasal spray, this study design is the most appropriate as this may form the base towards a future randomized, placebo-controlled trial.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Esketamine nasal spray (Spravato) for the treatment of therapy-resistant bipolar depression. An open-label pilot trial.
Plain-language title
Tests esketamine nasal spray in adults with hard-to-treat bipolar depressionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
26 November 2024